Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy
This trial has been completed.
|Phase||phase 1/phase 2|
|Start date||June 2013|
|End date||December 2016|
|Trial size||16 participants|
|Trial identifier||NCT01885936, Pro00046020|
In this study the study team proposes to investigate the efficacy of albuterol on motor function of individuals with Late Onset Pompe Disease (LOPD) who are receiving enzyme replacement therapy, given albuterol was well-tolerated in patients with Late Onset Pompe Disease.
|Endpoint classification||safety/efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, investigator)|
Number of participants with Adverse Events.
time frame: 52 weeks
Change in forced vital capacity from pulmonary function tests at 30 weeks and 52 weeks.
time frame: Baseline and weeks 30 and 52.
Change in 6 minute walk test
time frame: Weeks 6 and 52.
Male or female participants at least 18 years old.
Inclusion Criteria: 1. Diagnosis of Pompe disease by blood acid alpha-glucosidase assay and acid alpha-glucosidase gene sequencing, 2. Age: 18+ years at enrollment. 3. Receiving enzyme replacement therapy at standard dose (20 mg/kg every 2 weeks) for at least 52 weeks. 4. Subjects are capable of giving written consent. Exclusion Criteria: 1. Continuous invasive ventilation (via tracheostomy or endotracheal tube). 2. Clinically relevant illness within two weeks of enrollment including fever > 38.2 C, vomiting more than once in 24 hours, seizure, or other symptom deemed contraindicative to new therapy. 3. Chronic heart disease (Myocardial infarction in the past 2 months, arrhythmia, cardiomyopathy). 4. History of seizure disorder. 5. History of diabetes. 6. Hypokalemia. 7. History of hyperthyroidism. 8. Pregnancy. 9. Patients on a non-standard schedule for enzyme replacement therapy; for example, weekly infusions as opposed to infusions every two weeks. 10. Anti-rhGAA antibody titer > 1:100,000 11. History of hypersensitivity to Beta 2-agonist drugs such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol (Serevent).. 12. The use of the following medications: - diuretics (water pill); - digoxin (digitalis, Lanoxin); - beta-blockers such as atenolol (Tenormin), metoprolol (Lopressor), and propranolol (Inderal); - tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor); - Monoamine oxidase inhibitors such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate); or - bronchodilators such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol (Serevent), isoetharine (Bronkometer), metaproterenol (Alupent, Metaprel), or isoproterenol (Isuprel Mistometer) within 12 weeks prior to enrollment.
|Official title||A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy|
|Principal investigator||Dwight d Koeberl, MD, PhD|
Call for more information